Reference number(s)	
1160-C	



Reference number(s) 1160-C

Initial Prior Authorization with Quantity Limit Jublia

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Jublia	efinaconazole

Indications

FDA-approved Indications

Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Coverage Criteria

Onychomycosis of the Toenail(s)

Authorization may be granted when the requested drug is being prescribed for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes when ALL of the following criteria are met:

Jublia PA with Limit 1160-C P10-2024_R.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).
- The patient meets ONE of the following:
 - The patient has experienced an inadequate treatment response to an oral antifungal therapy (e.g., terbinafine, itraconazole).
 - The patient has experienced an intolerance to an oral antifungal therapy (e.g., terbinafine, itraconazole).
 - The patient has a contraindication that would prohibit a trial of an oral antifungal therapy (e.g., terbinafine, itraconazole).
- The requested drug is NOT being used in a footbath.
- If additional quantities are required, multiple toenails are being treated.

Quantity Limits Apply

Treatment of a single toenail: 4 mL per 21 days or 12 mL per 63 days

Treatment of multiple toenails: 16 mL per 21 days or 48 mL per 63 days

The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

Duration Of Approval (DOA)

• 1160-C: DOA: 12 months

References

- 1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; March 2022.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 10, 2024.
- 3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/10/2024).
- 4. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. American Academy of Family Physicians. 2021;104:359-368.
- 5. Centers for Disease Control (CDC) and Prevention. Treatment of Ringworm and Fungal Nail infections. Available at: https://www.cdc.gov/ringworm/treatment/index.html. Accessed September 10, 2024.

Jublia PA with Limit 1160-C P10-2024_R.docx

© 2025 CVS Caremark. All rights reserved.